All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Charles MullighanCo-Chair

Charles G. Mullighan is a member of the Department of Pathology, deputy director at the Comprehensive Cancer Center, and co-leader of the Hematological Malignancies Program at St. Jude Children’s Research Hospital, Memphis, US. He is also the medical director at St. Jude Biorepository. Charles received his training in medicine, hematology, and hematopathology in Adelaide, AU, and undertook doctoral studies in immunogenetics at the University of Oxford, UK. His research interests include the use of integrated genomic and epigenomic approaches to understand the pathogenesis and evolution of ALL and related disorders; defining the interaction of inherited and somatic genetic alterations in leukemogenesis; the use of in vitro and in vivo experimental approaches to model genomic abnormalities in leukemogenesis; and preclinical therapeutic testing to translate genomic discoveries to new treatment approaches in ALL.

|